Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lipid Lowering Medication · 1 trial · 1 indication
The percent change in fasting blood circulating serum TGs between baseline and 4 weeks of treatment.
| Arm | Type | Description |
|---|---|---|
| Group A | ACTIVE_COMPARATOR | 0.5g total CaPre™ from baseline to week 4 and 1.0g total CaPre™ from week 4 to week 8 |
| Group B | ACTIVE_COMPARATOR | 1.0g total CaPre™ from baseline to week 4 and 2.0g total CaPre™ from week 4 to week |
| Group C | ACTIVE_COMPARATOR | 2.0g total CaPre™ from baseline to week 4 and 4.0g total CaPre™ from week 4 to week 8 |
| Group D | OTHER | Standard of care |
| Group E | ACTIVE_COMPARATOR | 4.0g total CaPre™ from baseline to week 8 |
| Name | Type | Description |
|---|---|---|
| CaPre™ | DIETARY_SUPPLEMENT | 1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks |
| Lipid Lowering Medication | DRUG | Patient will be treated as per the Standard of care. |
Inclusion Criteria: * Male and female adults aged 18 to 75 years; * Fasting plasma levels of TG \> 2.28 and \< 10 mmol/L (200 and 877 mg/dL) on two occasions within 2 weeks (screening and baseline/part 1 visits). * Patients who are currently not on pharmacotherapy for hyperlipidemia and according t...
Lipid Lowering Medication is used for hypertriglyceridemia, a condition characterized by elevated levels of triglycerides in the blood. It is being developed as a small molecule treatment for this metabolic disorder. The drug is currently in clinical development and has completed a Phase 2 trial.
Lipid Lowering Medication is being developed by Grace Therapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol GRCE. The drug is currently in Phase 2 clinical development for the treatment of hypertriglyceridemia.
Lipid Lowering Medication is in Phase 2 clinical development. It has completed one Phase 2 trial, which was an active-controlled study in patients with mild-to-high hypertriglyceridemia. The drug is investigational and has not been approved by regulatory authorities.
Lipid Lowering Medication has completed one clinical trial, identified as NCT01516151. This Phase 2 study assessed the safety and efficacy of the drug in treating mild-to-high hypertriglyceridemia. The trial enrolled 289 participants in Canada and was active-controlled, meaning it compared the drug against an active comparator.
Yes, Lipid Lowering Medication is also known as NKPL66, which was referred to as CaPre in the clinical trial. The Phase 2 trial NCT01516151 evaluated NKPL66 (CaPre) for the treatment of hypertriglyceridemia. This alternative name may be used in scientific literature and clinical trial records.